Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials. We developed multimodal models for f-FTD disease progression and estimated clinical trial sample sizes in C9orf72, GRN and MAPT mutation carriers. Models included longitudinal clinical and neuropsychological scores, regional brain volumes and plasma neurofilament light chain (NfL) in 796 carriers and 412 noncarrier controls. We found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations using model-based patient selection, atrophy and NfL were the best endpoints, whereas clinical measures were potential endpoints in early symptomatic trials. f-FTD prevention trials are feasible but will likely require global recruitment efforts. These disease progression models will facilitate the planning of f-FTD clinical trials, including the selection of optimal endpoints and enrollment criteria to maximize power to detect treatment effects.Empirically based models of disease progression in familial frontotemporal dementia reveal the relative ordering of clinical, neuroimaging, and fluid biomarker changes and facilitate novel clinical trial designs.

Temporal order of clinical and biomarker changes in familial frontotemporal dementia / A.M. Staffaroni, M. Quintana, B. Wendelberger, H.W. Heuer, L.L. Russell, Y. Cobigo, A. Wolf, S.M. Goh, L. Petrucelli, T.F. Gendron, C. Heller, A.L. Clark, J.C. Taylor, A. Wise, E. Ong, L. Forsberg, D. Brushaber, J.C. Rojas, L. Vandevrede, P. Ljubenkov, J. Kramer, K.B. Casaletto, B. Appleby, Y. Bordelon, H. Botha, B.C. Dickerson, K. Domoto-Reilly, J.A. Fields, T. Foroud, R. Gavrilova, D. Geschwind, N. Ghoshal, J. Goldman, J. Graff-Radford, N. Graff-Radford, M. Grossman, M.G.H. Hall, G. Hsiung, E.D. Huey, D. Irwin, D.T. Jones, K. Kantarci, D. Kaufer, D. Knopman, W. Kremers, A.L. Lago, M.I. Lapid, I. Litvan, D. Lucente, I.R. Mackenzie, M.F. Mendez, C. Mester, B.L. Miller, C.U. Onyike, R. Rademakers, V.K. Ramanan, E.M. Ramos, M. Rao, K. Rascovsky, K.P. Rankin, E.D. Roberson, R. Savica, M.C. Tartaglia, S. Weintraub, B. Wong, D.M. Cash, A. Bouzigues, I.J. Swift, G. Peakman, M. Bocchetta, E.G. Todd, R.S. Convery, J.B. Rowe, B. Borroni, D. Galimberti, P. Tiraboschi, M. Masellis, E. Finger, J.C. van Swieten, H. Seelaar, L.C. Jiskoot, S. Sorbi, C.R. Butler, C. Graff, A. Gerhard, T. Langheinrich, R. Laforce, R. Sanchez-Valle, A. de Mendonça, F. Moreno, M. Synofzik, R. Vandenberghe, S. Ducharme, I. Le Ber, J. Levin, A. Danek, M. Otto, F. Pasquier, I. Santana, J. Kornak, B.F. Boeve, H.J. Rosen, J.D. Rohrer, A.L. Boxer. - In: NATURE MEDICINE. - ISSN 1078-8956. - 28:10(2022), pp. 2194-2206. [10.1038/s41591-022-01942-9]

Temporal order of clinical and biomarker changes in familial frontotemporal dementia

D. Galimberti;
2022

Abstract

Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials. We developed multimodal models for f-FTD disease progression and estimated clinical trial sample sizes in C9orf72, GRN and MAPT mutation carriers. Models included longitudinal clinical and neuropsychological scores, regional brain volumes and plasma neurofilament light chain (NfL) in 796 carriers and 412 noncarrier controls. We found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations using model-based patient selection, atrophy and NfL were the best endpoints, whereas clinical measures were potential endpoints in early symptomatic trials. f-FTD prevention trials are feasible but will likely require global recruitment efforts. These disease progression models will facilitate the planning of f-FTD clinical trials, including the selection of optimal endpoints and enrollment criteria to maximize power to detect treatment effects.Empirically based models of disease progression in familial frontotemporal dementia reveal the relative ordering of clinical, neuroimaging, and fluid biomarker changes and facilitate novel clinical trial designs.
Biomarkers; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Humans; Mutation; tau Proteins; Frontotemporal Dementia
Settore BIO/13 - Biologia Applicata
Article (author)
File in questo prodotto:
File Dimensione Formato  
Staffaroni et al.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 19.15 MB
Formato Adobe PDF
19.15 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/943681
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact